THE WOODLANDS, TX, March  04, 2026  (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) (&#34;Autonomix&#34; or the &#34;Company&#34;), a medical device company dedicated to advancing precision nerve-targeted treatments, today

AMIX

Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis

Autonomix Medical to Present Innovative Nerve-Targeting Technology at Major Conference

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>THE WOODLANDS, TX, March  04, 2026  (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) (&amp;#34;Autonomix&amp;#34; or the &amp;#34;Company&amp;#34;), a medical device company dedicated to advancing precision nerve-targeted treatments, today</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Autonomix Medical will showcase its innovative nerve-targeting technology at the CRT 2026 conference on March 7, which could enhance treatment options for chronic pain. This presentation aims to highlight clinical feasibility and potential broader applications, potentially enhancing investor confidence and fueling future growth for AMIX.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Dr. Nikola Cesarovic presents at CRT 2026 on March 7.</li><li>Presentation covers novel RF-based technique for nerve targeting.</li><li>Early outcomes suggest potential for broader applications in nerve modulation.</li><li>Increased clinical interest in nerve-targeted therapies may drive future growth.</li><li>Technology is investigational, not yet cleared for U.S. marketing.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Autonomix Medical, Inc. (AMIX)</strong>: Focusing on novel nerve-targeted treatments could revolutionize pain management.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>This falls under &#039;Industry News&#039; as it highlights advancements in medical technology and relates to a significant industry conference showcasing emerging treatments in cardiovascular and nerve-targeted therapies, crucial for market positioning.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Positive early outcomes could significantly boost AMIX&#039;s valuation.</li><li>New applications from the technology could attract future investments.</li><li>Increased awareness due to the conference may enhance market perception.</li><li>FDA clearance processes may accelerate if technology proves effective.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Presentation scheduled for March 7, 2026, at CRT 2026 in Washington, DC.</li><li>Technique utilizes RF ablation for peripheral nerve modulation.</li><li>Autonomix&#039;s technology focuses on chronic pain, particularly from pancreatic cancer.</li><li>The technology has not yet received FDA clearance for U.S. marketing.</li><li>CRT is a leading forum for interventional cardiovascular medicine.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Investors may consider buying AMIX in anticipation of positive market response post-conference.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify"><b>THE WOODLANDS, TX, March  04, 2026  (GLOBE NEWSWIRE) -- </b><a href="https://www.globenewswire.com/Tracker?data=rKj_Ar0AfuxheezwORIaZwAtf3Nn8CPP9phEQIw1SFQD7s3xoFt8F4jyzqOATt0G8zwzaHTaN0OpVSjY39Mvjg082EWvExZ8JsX9JA09JrGuRD57_GE-Q2T7NFZVLL3MEMBywkXY9GWyczzCGphTrdB9xWNP6ccpop2gzBEvWM0G0JpJB-enpUWP9W-QGFbPO83CzVS04qOE0I1b63hQqnAbnBoV8OC08n1Pj8lkOQ2mx6hTylHPL1LFajKC0_9suiGzm9wggYikDUr-dKpXKQ==" rel="nofollow" target="_blank">Autonomix Medical, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/AMIX">AMIX</a>) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Nikola Cesarovic, PhD, will present clinical feasibility and outcome data at the <a href="https://www.globenewswire.com/Tracker?data=8EfhO01BFuy4XexpqANHDCAKiShTPDOmueQt1hGjXL8lxgFX8F-kHMUTZ-MeFNo6LfefP3aMwOfkjOe2eHrOlLjolC2PV93DR93q4XcKPu8pyTOnEZEaD2HwihPULQ3E-m9UZASkAbmDDeNxJ33Ycg==" rel="nofollow" target="_blank">Cardiovascular Research Technologies (CRT) 2026 Meeting</a>, happening March 7-10, 2026, in Washington, DC.</p>  <p align="justify">The abstract titled, "<i>Novel Technique For Transvascular Peripheral Nerve Neurolysis Using Radiofrequency (RF) Ablation: Clinical Feasibility And Outcomes</i>," will be presented during the Top Abstract Session (S194) on Saturday, March 7 from 2:18 - 2:24p ET for Hypertension Therapies and Renal Denervation session. Dr. Cesarovic will deliver a six-minute presentation, highlighting clinical feasibility and early outcomes associated with a novel RF-based approach designed to selectively disrupt peripheral nerve activity via a transvascular approach. Autonomix's technology is engineered to identify and target specific nerve signals, potentially enabling differentiated therapeutic precision compared to conventional ablation techniques.</p>  <p align="justify">"This Top Abstract selection underscores the growing clinical interest in precision nerve-targeted therapies and highlights the potential of Autonomix's platform to enable controlled, transvascular peripheral nerve modulation," said Dr. Robert Schwartz, Co-Founder and Chief Medical Officer of Autonomix. "We believe these early feasibility findings support the broader applicability of our technology across multiple indications where peripheral nerve signaling plays a critical role."</p>  <p align="justify">CRT is one of the world's leading educational forums for interventional cardiovascular medicine, with Top Abstract podium selections representing the highest-scoring submissions based on scientific merit, innovation and clinical relevance. For more information, please visit the conference website <a href="https://www.globenewswire.com/Tracker?data=GNy2v1CmvLgJ5V2kFByhwFRjbJE8TW9P7MWe7BCaRmbeIaBZpfXSB7qKboM7BDFtp3WNJug-WE0YmLdW3JU0QA==" rel="nofollow" target="_blank">here</a>.</p>  <p align="justify"><b>About Autonomix Medical, Inc.</b></p>  <p align="justify">Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.</p>  <p align="justify">We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.</p>  <p align="justify">For more information, visit <a href="https://www.globenewswire.com/Tracker?data=mqCvCLew7kvtkwvzwSKQ44rNzlNBpzYgJ9wlWamupa9R7uvuft20g7DWn47_UTIggWKpofhfFm37VTQuVh-hnA==" rel="nofollow" target="_blank">autonomix.com</a> and connect with the Company on <a href="https://www.globenewswire.com/Tracker?data=KIXOT2Nc70WwS5LHHIWz-D1_3idozgp9WjDpKpeSg9Ru5ciGPwf38gWnDS4OZutNM6XlVelJ5331rq3Ngfcvvw==" rel="nofollow" target="_blank">X</a>, <a href="https://www.globenewswire.com/Tracker?data=kL3BLBF3lj4VFf-uWOTdv5-J-EJGYJIcWfz6ha1vbR76P_RMdAOuwUGk8IHDb4VdWSms2K6JtAbTwSvzrW5sqFgA2wo4qzxFKsVHNUORxFt4oj5vCFuDHmn77FxYCfCG" rel="nofollow" target="_blank">LinkedIn</a>, <a href="https://www.globenewswire.com/Tracker?data=QcvSFabUbDWrvvxMD0kCwFpL_rwbNfYwxZKhA1XI3KAfak-KIsCHi3aMMkiUONMJfriBfdW0uNZ94h0OOKNxdvrkLeUhWKlW5yuF1WLuipk=" rel="nofollow" target="_blank">Instagram</a> and <a href="https://www.globenewswire.com/Tracker?data=jL-RUuatKe2nfXaJ1rjFu8FXVV5S7NgMCiyI4oV7ocS8KsjwWJponxZkTMFYhsWE_eyzZ1nkIarEWib3g0RSoH4jJLWEQ4FMyqirRqi_0M2PvZXAZ4QQZseCLxomOfhC" rel="nofollow" target="_blank">Facebook</a>.</p>  <p align="justify"><b>Forward Looking Statements</b></p>  <p align="justify">Some of the statements in this release are "forward-looking statements," which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as "should," "might," "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," and "proposes." Forward-looking statements in this press release include expectations regarding the potential effectiveness and clinical benefits of Autonomix&#39;s nerve-targeted treatments for pancreatic cancer pain and other conditions.<br></br><br></br>Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.</p>  <p align="justify"><b>Investor and Media Contact</b></p>  <p align="justify">JTC Team, LLC<br></br>Jenene Thomas <br></br>908.824.0775 <br></br><a href="https://www.globenewswire.com/Tracker?data=mqCvCLew7kvtkwvzwSKQ4y5RfYGLGsWa28-m_MW4rGsMw8dCmCBX5hc2uo59a2Q6dBDZ7UBn8QbN87ggvYaVw8l6VixQiE-30UCVUvu0x2M=" rel="nofollow" target="_blank">autonomix@jtcir.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY2NTQxOSM3NDY2NDA0IzUwMDExOTk5Mg=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZGE5YTZlYjctZmUxYi00MTM4LThmYzgtN2YxZGRiMmY1ZDUzLTUwMDExOTk5Mi0yMDI2LTAzLTA0LWVu/tiny/Autonomix-Medical-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/8b0ba1bc-43b1-4445-b895-712da30f7df8"><img src="https://ml.globenewswire.com/media/8b0ba1bc-43b1-4445-b895-712da30f7df8/small/logo-png.png" border="0" width="150" height="87" alt="Primary Logo"></img></a></p>

Autonomix Medical will showcase its innovative nerve-targeting technology at the CRT 2026 conference on March 7, which could enhance treatment options for chronic pain. This presentation aims to highlight clinical feasibility and potential broader applications, potentially enhancing investor confidence and fueling future growth for AMIX.

autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis

Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Industry News

Related News